National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
Contains
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

trastuzumab  Patient Information
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms:anti-c-erB-2
anti-c-erbB2 monoclonal antibody
anti-ERB-2
anti-erbB-2
anti-erbB2 monoclonal antibody
anti-HER2/c-erbB2 monoclonal antibody
anti-p185-HER2
monoclonal antibody c-erb-2
monoclonal antibody HER2
US brand name:Herceptin
Abbreviations:MOAB HER2
rhuMAb HER2


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov